Adjuvant Imatinib Prolongs RFS and OS in Patients with Resected GIST Harbouring KIT Exon 9 Mutations By Ogkologos - March 10, 2026 360 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an international retrospective cohort study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Mom with Breast Cancer Who Had A Year to Live Goes... April 2, 2019 Talazoparib Beyond BRCA Prospective Study Identifies the Sensitivity of gPALB2-Associated Breast... October 25, 2022 Telehealth Can Save People with Cancer Time, Travel, and Money February 16, 2023 Three-Drug Regimen Improves Protection against GVHD after Stem Cell Transplant July 14, 2023 Load more HOT NEWS Second- or Third-Line Treatment with Tisotumab Vedotin Results in Greater Efficacy... FDA Approves Polatuzumab Vedotin-piiq for Previously Untreated Diffuse Large B-Cell Lymphoma,... Cómo solicitar Medicare cuando tiene cáncer Reunión anual de la American Society of Clinical Oncology de 2022:...
